THE DEAL, AT A GLANCE

Allotera Therapeutics

From the announcement

Cell therapy development

What it doesAllotera is developing Sofi-cel as an allogeneic, healthy donor-derived CAR-T cell therapy intended to address these challenges and provide an off-the-shelf treatment…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

02What happenedAllotera Therapeutics raised $35M, announced 2026-07-08From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03Why it mattersAllotera Therapeutics' $35M financing is a mid-market Healthcare & Life Sciences capital-flow signal for off-the-shelf CAR-T approaches in T-cell cancers, not an outlier…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Allotera Therapeutics · Financing Record

Explore source-linked visual explanations for Allotera Therapeutics. Unsupported claims are withheld while source review continues.

Record 7904 · Recorded date: 2026-07-08

Explore company records →

Allotera Therapeutics

Allotera Therapeutics · Financing Record

Know which funding rounds matter before the first call.